As of 2025-05-21, the Intrinsic Value of Mayne Pharma Group Ltd (MYX.AX) is (71.96) AUD. This MYX.AX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 6.48 AUD, the upside of Mayne Pharma Group Ltd is -1,210.50%.
The range of the Intrinsic Value is (155.94) - (48.12) AUD
Based on its market price of 6.48 AUD and our intrinsic valuation, Mayne Pharma Group Ltd (MYX.AX) is overvalued by 1,210.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (155.94) - (48.12) | (71.96) | -1210.5% |
| DCF (Growth 10y) | (39.32) - (110.17) | (55.14) | -950.9% |
| DCF (EBITDA 5y) | (15.58) - (18.45) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (19.86) - (22.48) | (1,234.50) | -123450.0% |
| Fair Value | -7.95 - -7.95 | -7.95 | -222.72% |
| P/E | (18.07) - (18.04) | (18.33) | -382.9% |
| EV/EBITDA | (4.58) - (3.61) | (4.27) | -165.9% |
| EPV | (7.83) - (10.11) | (8.97) | -238.4% |
| DDM - Stable | (19.45) - (83.60) | (51.52) | -895.1% |
| DDM - Multi | (26.11) - (87.26) | (40.19) | -720.2% |
| Market Cap (mil) | 526.50 |
| Beta | 0.43 |
| Outstanding shares (mil) | 81.25 |
| Enterprise Value (mil) | 512.65 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.72% |
| Cost of Debt | 5.00% |
| WACC | 7.46% |